PME Full Year Results
| Stock | Pro Medicus Ltd (PME.ASX) |
|---|---|
| Release Time | 18 Aug 2026, 9:32 a.m. |
| Price Sensitive | Yes |
Pro Medicus Ltd FY26 Results
- FY26 underlying NPAT $144.7m, up +24.1%
- Revenue $261.7m, up +22.9%
- Fully-franked final dividend 37c per share
Pro Medicus Ltd (PME) has delivered a FY26 underlying Net Profit After Tax (NPAT) of $144.7 million, up +24.1% year-on-year. Revenue from ordinary activities was $261.7 million, up +22.9%. Reported NPAT was $265.3 million, up +130.3%. Cash and other financial assets at the end of the period were $252.3 million, an increase of +19.7%. The company remains debt-free. Fully-franked final dividend of 37c per share, making total dividends for the year 69c, an increase of +25.5%. On a constant currency basis, excluding the impact of year-on-year currency movements, annual revenue was $273.5 million, up +28.4%, underlying EBIT on constant currency was $206.0 million, up +30.6%, and underlying NPAT on constant currency was $154.5 million, up 32.5%.
FY26 underlying NPAT $144.7m, Revenue $261.7m, Cash assets $252.3m
CEO Dr Sam Hupert expressed satisfaction with the results and expects continued growth in FY27.